Yago Nieto

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Transplantation for refractory germ cell tumors: does it really make a difference?
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX, 77030, USA
    Curr Oncol Rep 15:232-8. 2013
  2. ncbi request reprint Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 19:410-7. 2013
  3. ncbi request reprint High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies
    Yago Nieto
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030
    Biol Blood Marrow Transplant 18:1677-86. 2012
  4. doi request reprint High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    Curr Opin Oncol 21:150-7. 2009
  5. pmc Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy
    Y Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Cancer 97:391-7. 2007
  6. ncbi request reprint Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, Unit 423, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4405-13. 2007
  7. doi request reprint Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer
    Yago Nieto
    Department of Medical Oncology, Clinica Universitaria de Navarra, Pamplona, Spain
    Cancer Chemother Pharmacol 65:457-65. 2010
  8. ncbi request reprint Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:1324-37. 2007
  9. pmc Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines
    Benigno C Valdez
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Exp Hematol 40:800-10. 2012
  10. pmc Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications
    Benigno C Valdez
    Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Exp Hematol 41:719-30. 2013

Detail Information

Publications45

  1. doi request reprint Transplantation for refractory germ cell tumors: does it really make a difference?
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX, 77030, USA
    Curr Oncol Rep 15:232-8. 2013
    ..Prognostic models have been developed that allow to prospectively identify poor prognosis patients that might benefit from novel HDC-based approaches...
  2. ncbi request reprint Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 19:410-7. 2013
    ..9, P = .008, HR for OS = 1.8, P = .07). Gem-Bu-Mel improved outcomes in this cohort analysis of patients with refractory/poor-risk relapsed HL and merits evaluation in randomized phase III trials...
  3. ncbi request reprint High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies
    Yago Nieto
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030
    Biol Blood Marrow Transplant 18:1677-86. 2012
    ..In conclusion, gemcitabine/busulfan/melphalan is a feasible regimen with substantial activity against a range of lymphoid malignancies. This regimen merits further evaluation in phase II and III trials...
  4. doi request reprint High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    Curr Opin Oncol 21:150-7. 2009
    ..We review here the main publications in this field since 2006, focusing on updates of randomized trials comparing HDC with standard-dose chemotherapy...
  5. pmc Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy
    Y Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Cancer 97:391-7. 2007
    ..In conclusion, tumour angiogenesis, expressed as MVD, is a major independent prognostic factor in breast cancer patients with extensive axillary involvement...
  6. ncbi request reprint Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, Unit 423, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4405-13. 2007
    ..We hypothesized that EGFR status plays a major prognostic role in this setting, through expression, activation, or the presence of its mutated variant EGFRvIII...
  7. doi request reprint Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer
    Yago Nieto
    Department of Medical Oncology, Clinica Universitaria de Navarra, Pamplona, Spain
    Cancer Chemother Pharmacol 65:457-65. 2010
    ..We hypothesized that sequential treatment with dose-dense epirubicin/cyclophosphamide (EC) and docetaxel/capecitabine would be active and tolerable in the adjuvant/neoadjuvant setting...
  8. ncbi request reprint Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:1324-37. 2007
    ..The resulting gemcitabine/docetaxel/melphalan/carboplatin combination was highly active in refractory cancers and should be further tested in disease-specific trials...
  9. pmc Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines
    Benigno C Valdez
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Exp Hematol 40:800-10. 2012
    ..This study provides a rationale for an ongoing clinical trial in our institution using (BMG+suberoylanilide hydroxamic acid) as pre-hematopoietic stem cell transplantation conditioning for lymphoma...
  10. pmc Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications
    Benigno C Valdez
    Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Exp Hematol 41:719-30. 2013
    ..Our results provide a rationale for clinical trials incorporating [Gem+Clo] combinations as part of conditioning therapy for high-risk patients with MM undergoing HSCT. ..
  11. ncbi request reprint A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas Electronic address
    Biol Blood Marrow Transplant 19:1453-8. 2013
    ..6 versus 9.6 months in patients with <VGPR, P = .05). OS was similar across all variables. We conclude that FM100 and FM140 may result in similar patient outcomes after allo-HCT for MM...
  12. ncbi request reprint Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:412-20. 2011
    ..Intravenous Bu-Mel was well tolerated. Disease control wa encouraging, and should be explored in larger phase II studies...
  13. doi request reprint Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation
    Li Mei Poon
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Biol Blood Marrow Transplant 19:1059-64. 2013
    ..8). Our data provide more insight into the disease behavior and treatment outcomes of ALL at relapse after HSCT against which future trials may be compared...
  14. doi request reprint Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization
    Veronica R Smith
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Hematol 88:754-7. 2013
    ..93 × 10(6) /kg of body weight. The median CD34+ cell dose collected for patients with multiple myeloma was 8.81 × 10(6) /kg of body weight. Plerixafor was well tolerated; no grade 2 or higher non-hematologic toxic effects were observed...
  15. doi request reprint Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 17:1490-6. 2011
    ..Our results suggest that age alone should not be the primary reason for exclusion from receiving myeloablative reduced-toxicity conditioning with i.v. Bu-Flu preceding transplantation in patients with AML/MDS...
  16. doi request reprint Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial
    Muzaffar H Qazilbash
    Department of Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:1401-7. 2008
    ..Addition of ATO + AA to high-dose melphalan is safe and well tolerated as a preparative regimen for MM...
  17. doi request reprint Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma
    Uday Popat
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:718-23. 2009
    ..In patients with multiple myeloma, prior lenalidomide therapy is associated with failure of stem cell mobilization with filgrastim. Remobilization with chemotherapy and filgrastim is usually successful in these patients...
  18. ncbi request reprint Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation
    Yago Nieto
    Bone Marrow Transplant Programs, University of Navarra, Pamplona, Spain
    Biol Blood Marrow Transplant 12:217-25. 2006
    ..5%, 50%, and 40%, respectively. In conclusion, the use of tacrolimus/MMF after MSD NST is associated with encouraging rates of GVHD control...
  19. ncbi request reprint Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation
    Fleur M Aung
    Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 160:798-805. 2013
    ..Hence, after major ABO-mismatched HSCT, the incidence of PRCA was 7·5% and it resolved spontaneously or after withdrawal of immunosuppression in the majority of patients...
  20. ncbi request reprint Docetaxel administered during pregnancy for inflammatory breast carcinoma
    Yago Nieto
    Department of Medical Oncology, University of Navarra, Pamplona, Spain
    Clin Breast Cancer 6:533-4. 2006
    ..After delivery of a healthy child, she underwent surgery, which showed tumor downstaging to pT0 N2, followed by radiation therapy and hormone therapy. This report suggests the safety of docetaxel after the first trimester of pregnancy...
  21. doi request reprint Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation
    Carlos A Ramos
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 16:686-94. 2010
    ..Our data suggest that seropositivity for HBcAb and seronegativity for HBsAg at the time of transplantation does not seem to adversely affect outcome after allo-HSCT...
  22. pmc Cord-blood engraftment with ex vivo mesenchymal-cell coculture
    Marcos de Lima
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, USA
    N Engl J Med 367:2305-15. 2012
    ..We hypothesized that engraftment would be improved by transplanting cord blood that was expanded ex vivo with mesenchymal stromal cells...
  23. ncbi request reprint Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, USA
    Biol Blood Marrow Transplant 18:1835-44. 2012
    ..These results indicate that a TCR graft followed by effective control of GVHD posttransplantation may lower NRM and improve survival after haploidentical SCT...
  24. pmc Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines
    Benigno C Valdez
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Leuk Lymphoma 53:973-81. 2012
    ..Our results provide a preclinical basis for a clinical trial on using [2 NAs + Bu ± SAHA] combinations as conditioning therapy for patients with chemotherapy-refractory lymphoma undergoing HSCT...
  25. ncbi request reprint A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects
    Roy B Jones
    Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 10:276-82. 2004
    ..Further, we suggest that amifostine use with BCNU in other contexts and with clinically achievable doses is unlikely to protect the lung from BCNU-associated acute injury...
  26. doi request reprint Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma
    Hong Yang
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer Res 71:5040-9. 2011
    ....
  27. ncbi request reprint Transplantation of ex vivo expanded cord blood
    Elizabeth J Shpall
    University of Colorado Adult Bone Marrow Transplant Program, Denver, USA
    Biol Blood Marrow Transplant 8:368-76. 2002
    ..This study demonstrates that the CD34 selection and ex vivo expansion of CB prior to transplantation of CB is feasible. Additional accrual will be required to assess the clinical efficacy of expanded CB progenitors...
  28. pmc Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation
    Michal Mego
    1 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 7 Current Address National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovak Republic
    J Cancer 3:369-80. 2012
    ..Conclusion: Our data suggest that CTC and CTCs with EMT are prognostic in MBC patients undergoing HDCT followed by AHSCT...
  29. ncbi request reprint Prognostic value of nodal ratios in node-positive breast cancer
    Wendy A Woodward
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:2910-6. 2006
    ..Here we examine the data supporting the use of nodal ratios in breast cancer prognosis and consider the potential advantages and disadvantages of including nodal ratios in breast cancer staging...
  30. ncbi request reprint Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule
    M Santisteban
    Departamento de Oncología Médica, Clinica Universitaria de Navarra, Pamplona, Spain
    Clin Transl Oncol 9:465-7. 2007
    ....
  31. ncbi request reprint Stem-cell transplantation for the treatment of advanced solid tumors
    Yago Nieto
    University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B 190, Denver, CO 80262, USA
    Springer Semin Immunopathol 26:31-56. 2004
    ..This article reviews the results of the main phase II and III studies of HDC with ASCT, as well as the preliminary experience using allogeneic transplantation for solid tumors...
  32. ncbi request reprint Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, CO, USA
    Am J Clin Oncol 28:248-54. 2005
    ..The debate about the age effect in this population remains unsettled...
  33. ncbi request reprint Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, Colorado, USA
    Biol Blood Marrow Transplant 11:297-306. 2005
    ..The notable activity of this regimen in treatment-refractory patients warrants its further evaluation...
  34. ncbi request reprint Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant
    Yago Nieto
    Bone Marrow Transplant Program and Departments of Pathology and Biostatistics, University of Colorado, Denver, Colorado 80262, USA
    Clin Cancer Res 10:5076-86. 2004
    ....
  35. ncbi request reprint Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer
    Yago Nieto
    Bone Marrow Transplant Program and Department of Biostatistics, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Cancer Res 10:7136-43. 2004
    ....
  36. ncbi request reprint High-dose chemotherapy for breast cancer: is another look warranted?
    Yago Nieto
    Blood and Marrow Transplant Program, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B 190 Denver, CO 80262, USA
    Curr Opin Oncol 16:114-9. 2004
    ..The authors review the main research results of high-dose chemotherapy for breast cancer in 2002 to 2003...
  37. ncbi request reprint Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support
    Yago Nieto
    Bone Marrow Transplant Program, University of Colorado, Denver 80262, USA
    Biol Blood Marrow Transplant 10:415-25. 2004
    ..2). In multivariate analyses, the presence of OTCs had an independent adverse effect on outcome in HRPBC, but not MBC. Our observations imply a direct role of OTCs in posttransplantation relapse in HRPBC...
  38. ncbi request reprint DNA-binding agents
    Yago Nieto
    University of Colorado Bone Marrow, Transplant Program, Denver 80262, USA
    Cancer Chemother Biol Response Modif 21:171-209. 2003
  39. ncbi request reprint Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, Colorado 80262, USA
    Clin Cancer Res 10:2609-17. 2004
    ..dissected nodes), tumor size, hormone receptors, and HER2. In the present study we intended to test this model prospectively in a second patient cohort. In addition, we analyzed the long-term overall outcome of our HDC trials...
  40. doi request reprint The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review
    Denise M Oliansky
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Biol Blood Marrow Transplant 14:137-80. 2008
    ..conventional conditioning in older (>60 years) and intermediate (40-60 years) aged adults? (4) What is the impact on survival outcomes of unrelated donor HSCT vesus chemotherapy in younger (<40 years) adults with high risk disease?..
  41. ncbi request reprint Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program and Department of Pathology, University of Colorado, Denver, CO 80262, USA
    J Clin Oncol 20:707-18. 2002
    ..To study prognostic factors after high-dose chemotherapy (HDC) for patients with stage IV oligometastatic breast cancer...
  42. ncbi request reprint The evolution of the evidence-based review: evaluating the science enhances the art of medicine--statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation
    Roy Jones
    Biol Blood Marrow Transplant 11:819-22. 2005
  43. ncbi request reprint The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer
    Yago Nieto
    University of Colorado School of Medicine, Denver, CO 80262, USA
    Haematologica 88:201-11. 2003
    ..In most cases, the results of these trials are premature and contradictory. Furthermore, they have often been interpreted, incorrectly in this author's judgment, as proof of lack of benefit of HDC...
  44. ncbi request reprint DNA-binding agents
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, CO 80262, USA
    Cancer Chemother Biol Response Modif 22:163-203. 2005
  45. ncbi request reprint DNA-binding agents
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, 4200 East Ninth Avenue, B 190, Denver, CO 80262, USA
    Cancer Chemother Biol Response Modif 20:197-225. 2002